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Abstract
Background: Genome-wide linkage studies for Alzheimer's disease have implicated several
chromosomal regions as potential loci for susceptibility genes.
Methods: In the present study, we have combined a selection of affected relative pairs (ARPs)
from the UK and the USA included in a previous linkage study by Myers et al. (Am J Med Genet,
2002), with ARPs from Sweden and Washington University. In this total sample collection of 397
ARPs, we have analyzed linkage to chromosomes 1, 9, 10, 12, 19 and 21, implicated in the previous
scan.
Results: The analysis revealed that linkage to chromosome 19q13 close to the APOE locus
increased considerably as compared to the earlier scan. However, linkage to chromosome 10q21,
which provided the strongest linkage in the previous scan could not be detected.
Conclusion: The present investigation provides yet further evidence that 19q13 is the only
chromosomal region consistently linked to Alzheimer's disease.
Background
Alzheimer's disease (AD) is the most common form of
dementia and the number of affected individuals rises
dramatically with an aging population. Age is the most
prominent risk factor, but genetics is also important for
the risk of developing AD. Three genes are known to cause
autosomal dominant early-onset AD: the amyloid beta
precursor protein (APP) on chromosome 21 [1], preseni-
lin 1 (PSEN1) on chromosome 14 [2] and presenilin 2
(PSEN2) on chromosome 1 [3]. For the much more com-
mon sporadic AD with later onset, apolipoprotein E
(APOE) on chromosome 19q13 is so far the only identi-
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fied susceptibility gene with consistently demonstrated
association [4].
The ε4 allele of APOE is estimated to account for less than
a third of the lifetime risk for AD [5,6] and simulation
studies have predicted at least four additional genetic loci
contributing to age at onset [7]. Although such calcula-
tions are by necessity based on certain assumptions, they
support the possibility that there are more genetic suscep-
tibility factors for AD to be identified. Genome-wide link-
age studies using affected sib-pairs or families have
implicated a number of chromosomal loci to hold suscep-
tibility genes [8-14]. Regions on chromosomes 9, 10, 12
and 19 seem to be the most replicated, although the exact
position of the peaks can differ substantially.
In the present study, we have combined a selection of
affected relative pairs (ARPs) from the UK and the USA
included in an earlier linkage study by Myers et al. [10].
We have modified the original sample collection by
excluding the NIMH sample and samples with ambiguous
phenotypes, as well as by adding sample collections from
Sweden and Washington University. We have analyzed
linkage to regions on chromosomes 1, 9, 10, 12, 19 and
21, previously implicated in the study by Myers et al.
Methods
Samples
A total of 580 individuals from 261 families affected by
late onset AD (family mean age at onset ≥60 years)
divided into 397 ARPs were analyzed in this study. Out of
these, 116 ARPs were collected in Sweden, 87 ARPs in the
UK and 194 ARPs in the USA (Indiana Alzheimer Disease
Center National Cell Repository and Washington Univer-
sity, St. Louis, MO) (Table 1).
The ARPs were selected from families where at least one
relative pair was diagnosed with possible, probable or def-
inite AD according to NINCDS-ADRDA diagnostic criteria
[15]. All available family members, including unaffected
relatives, were sampled and genotyped after informed
consent had been collected from each participating indi-
vidual or next of kin. Only Caucasian families were
included to reduce potential genetic heterogeneity. This
study was approved by local and national ethics commit-
tees.
Samples from the UK and the Indiana Alzheimer Disease
Center National Cell Repository were also included in the
study by Myers et al. To improve power of the present
study, samples with ambiguous phenotypes were
removed and new samples were added. This resulted in a
total of 244 affected individuals from the UK and USA
samples (129 ARPs) that were also genotyped in the study
by Myers et al. but with another microsatellite marker set.
Twelve of the families from Sweden were analyzed in Gie-
draitis et al. 2006 [16]. There is also a likely overlap with
the Swedish samples used in the present study and the
sample collection used by Sillén et al. [13,14], but the
extent of this overlap is unknown to us.
Genotyping
A total of 100 microsatellite markers on chromosomes 1,
9, 10, 12, 19 and 21 also used in a study by Blacker et al.
[8] were included. The markers had an average spacing of
9.4 cM and an average genotyping success rate of 86%
(Table 2 and Additional file 1). In addition, APOE was
included as a genetic marker. Data from an additional 170
microsatellite markers located on other chromosomes
and with an average genotyping success rate of <80% were
included in the analysis of family structure, but not in the
linkage analysis.
Amplification of the microsatellite markers was per-
formed by multiplex PCR and the resulting fragments
were separated according to size on an ABI PRISM 3700
(Applied Biosystems, Foster City, CA, USA). For quality
control, each run included two CEPH samples (1331-01
and 1331-02) [17] and two water samples.
The Genotyper software v3.7 (Applied Biosystems) was
used for allele calling. Marker order and intermarker dis-
tances were obtained from the Marshfield reference map
[18]. APOE genotyping was performed at the respective
research center.
Table 1: Sample information
Sample PED IND AIND ASP ACP APOE ε4+ APOE ε4- AAO ± SD
SWE 52 168 130 102 14 87 10 69.1 ± 6.2
UK 70 148 148 87 0 51 16 75.0 ± 5.9
USA 139 369 302 191* 3 143 16 72.6 ± 6.1
Total 261 685 580 380 17 281 42 72.4 ± 5.5
PED: number of pedigrees, IND: number of genotyped individuals, AIND: number of genotyped affected individuals, ASP: number of genotyped 
affected sib-pairs, ACP: number of genotyped pairs of affected first cousins, APOE ε4+: number of ARPs where both individuals have at least one 
APOE ε4 allele, APOE ε4-: number of ARPs where neither individual has an APOE ε4 allele, AAO: age at onset, SD: standard deviation. * Including one 
half-sib pair.
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Statistical analysis
Family structures were verified through the Graphical rela-
tionship representation software (GRR) [19]. Mendelian
errors were identified and allele frequencies for selected
microsatellite markers were calculated including all avail-
able individuals using the MENDEL v8.0 software [20].
Allele frequencies were calculated for the total sample as
well as for each of the analyzed subgroups: SWE, UK USA,
APOE ε4+ (ARPs where both individuals have at least one
APOE ε4 allele), and APOE ε4- (ARPs where neither indi-
vidual has an APOE ε4 allele). File conversion was per-
formed using Mega v4.0 [21].
Allele sharing multipoint LOD scores (MLS) and two-
point LOD scores (TLS) were calculated for all groups
using the Allegro v2.0 software [22]. As suggested by the
software authors, an exponential model with scoring
function Spairs and family weighting option "power: 0.5"
was used. Significance levels of detected MLSs in the total
sample and the analyzed subgroups were simulated
through 1000 replications using the actual data set from
the selected chromosomes.
Results
In order to ensure high quality of the data included in the
analysis, the GRR program was used on all available gen-
otypes, including data from 270 microsatellite markers.
This prompted us to exclude samples which displayed
deviations from the expected average allele sharing
between sibs or other family members. Having performed
this quality check, 580 affected individuals from 261 ped-
igrees remained and were included in the analyses (Table
1).
The focus of this study was to further explore previously
implicated linkage peaks from a genome scan by Myers et
al. [10]. Both studies include samples from the UK and
USA, whereas the NIMH sample used in Myers et al. was
not included in the present scan, and samples from Swe-
den and Washington University were added. Using this
modified sample collection, linkage to chromosomes 1, 9,
10, 12, 19 and 21 was analyzed in the whole sample and
in subgroups based on sample origin or APOE ε4 status.
Chromosome 19q13 demonstrated the highest MLS of
3.0 in the total sample, increasing to 8.3 in the APOE ε4+
subsample. Chromosome 1p36 revealed an MLS of 3.5 in
the UK subgroup and chromosome 10p15 showed an
MLS of 2.4 in the APOE ε4- subgroup. The region span-
ning chromosome 10q22-25 showed MLSs of 1.3, 1.8 and
1.9 in the total sample, the APOE ε4- and the USA sub-
groups, respectively (Table 3). Results from this linkage
analysis have been depicted in Figure 1 with the positions
of linkage peaks from Myers et al. denoted for compari-
son.
Using data from the selected chromosomes, significance
threshold levels were simulated for the total samples, as
well as for the respective subgroups. After this simulation,
linkage to chromosomes 19q13 in the total sample and
the APOE ε4+ subgroup and to 1p36 in the UK subgroup
are considered significant according to the definition by
Lander and Kruglyak [23] (Table 3).
Discussion
In the past decade there have been a number of attempts
at identifying AD linkage regions using affected sib-pairs
or extended families [8-14]. Although results have varied
considerably and have sometimes been difficult to repli-
cate, the most convincing linkage peaks have been
reported from chromosomes 9, 10, 12, and 19.
In the present study, linkage peaks on chromosomes 1, 9,
10, 12, 19 and 21, previously implicated in a whole
genome scan by Myers et al. have been further analyzed
using a modified version of the original sample with an
added collection of ARPs from Sweden and Washington
University. We could detect significant linkage to chromo-
some 19q13 in the immediate vicinity of the APOE locus.
This linkage peak was noticeably increased from the scan
by Myers et al. and the Swedish sample contributed con-
siderably to the improved linkage (Table 3). The influence
of the APOE locus on AD has been correlated to a lower
Table 2: Microsatellite marker information
Chromosome Number of microsatellite markers Average intermarker distance (cM) Genotyping success rate (%)
1 31 8.9 86.8
9 15 10.7 85.0
10 20 8.8 85.0
12 18 9.4 86.0
19 10 10.1 85.8
21 6 11.0 85.7
TOTAL 100 9.4 85.8
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Linkage resultsFigur 1
Linkage results. Linkage across selected chromosomes in the whole sample and the APOE ε4+ and APOE ε4- subgroups. Y-
axes on all graphs represent MLS and X-axes are distance from pter in cM. MLS peaks (± 5 cM) from Myers et al. are indicated 
below the graphs.
Table 3: Maximum MLS and (TLS) ≥1 from the present study
Chr region Nearest marker (cM) ALL SWE UK USA APOE ε4+ APOE ε4-
1p36 D1S3669 (37) - - 3.5b (3.3b) - - -
1p32 D1S3728 (85) - - - - - 1.2
10p15 D10S1218 (5) 1.5a - - 1.5a - 2.4a (1.3)
10q22 D10S2327 (105) - - - - - 1.8a
10q25 D10S1237 (135) 1.3 (1.1) - - 1.9a (1.4) - -
10q26 D10S212 (171) (1.2) - - 1.1 - -
12q13 D12S398 (68) (1.5a) 1.3 (1.4) - - - -
12q23 PAH (109) - 1.1 (1.3) - - - -
12q24 D12S395 (137) - - - 1.0 - (1.6a)
12q24 D12S392 (166) - 1.1 - - - -
19p13 D19S586 (36) - 1.7a - - 1.5 -
19q13 D19S178 (68) 3.0b (2.5b) 1.9a (1.6a) - 1.1 8.3b (7.3b) 1.2
21q21 D21S1437 (13) - - - - - 1.5a (1.6a)
21q22 D21S1446 (58) (1.3) - - - 1.0 (1.2) -
Within each linkage region, the marker closest to the highest MLS has been denoted with its position in cM. Threshold levels were estimated from 
simulation analysis of the selected chromosomes. aSuggestive and bsignificant linkage for the respective linkage region and sample group according 
to Lander and Kruglyak [23].
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age at onset [4,24], as further demonstrated in our recent
analysis of the chromosome 19 linkage [25]. Accordingly,
linkage analysis of the NIMH cohort by Blacker et al. dem-
onstrated the highest linkage to chromosome 19q13 in
their subsample with earlier disease onset, whereas no
linkage to this region was detected in their late onset sam-
ple [8]. The only other significant linkage found in the
present study was to chromosome 1p36 in the UK sub-
sample. However, this peak was neither detected in the
other subgroups, nor in the total sample.
In the original whole genome scan by Myers et al., the
most significant linkage peak was demonstrated on chro-
mosome 10q21 (82 cM) in the whole sample. Blacker et
al. also found linkage in the region, to chromosome
10q22 (92 cM) in their total collection of NIMH samples.
In the present study, we could not detect linkage to chro-
mosome 10q21, even though a suggestive linkage of MLS
1.8 was detected to chromosome 10q22 (105 cM) in the
APOE ε4- sample. Although the sample size in the present
study is smaller than in the study by Myers et al. (380 and
451 ASPs, respectively), the previous study by Kehoe et al.
[9] using 292 ASPs and including overlapping samples
with the Myers study also detected linkage to chromo-
some 10q21. This suggests that the absence of a linkage
peak on chromosome 10q21 in the present study might
be due to sample differences between the studies rather
than sample size. However, we cannot completely exclude
that our linkage to chromosome 10q22 in the APOE ε4-
subsample coincides with the previously detected linkage
to chromosome 10q21-22, although the positions of
these peaks differ by 13-23 cM. Certain caution is also
called for as the APOE ε4- subsample is rather limited in
size (42 ARPs).
Inconsistent results between linkage studies might reflect
heterogeneity in sample cohorts, including age at onset,
ethnic background and diagnostic criteria. Our finding of
significant linkage to chromosome 19q13, but to no other
regions in the total sample in combination with the
results presented by Blacker et al., suggests that finding sig-
nificant linkage to both chromosome 19q13 and addi-
tional regions in the same sample is uncommon.
In the past few years, whole genome association studies
have successfully identified susceptibility loci for a
number of complex conditions. However, APOE is so far
the only locus demonstrating strong association to AD
[26-28]. Sample sizes have turned out to be crucial and
sample collections including thousands of cases have
been analyzed for association [29]. Increasing the number
of samples in analyses also of ARPs would most likely be
beneficial for the outcome and therefore further efforts to
combine different sample collections should be made. It
has been suggested that data from linkage analysis of
affected sib-pairs could also be used to verify candidate
susceptibility genes from association studies, since the fre-
quency of a risk allele is expected to be higher in siblings
sharing the locus than in population based cases [30].
Conclusion
In this linkage study, we have analyzed a sample collec-
tion of AD ARPs from Sweden, the UK and the USA for
linkage to chromosomes 1, 9, 10, 12, 19 and 21, impli-
cated in the previous study by Myers et al. [10]. The high-
est linkage was detected on chromosome 19q13 close to
the APOE gene. This linkage was extensively contributed
by the Swedish samples, which has a lower average age at
onset than the other subgroups. There was no evidence of
the previously demonstrated linkage to chromosome
10q21 in the whole sample collection, and the relevance
of the suggestive linkage within the APOE ε4- subgroup to
chromosome 10q22 is somewhat uncertain due to the
altered position of the peak and the restriction to this sub-
group only. Our study demonstrates that chromosome
19q13 including APOE, at this point, is the only consist-
ently linked locus for AD. This is also supported by
genome wide association studies, demonstrating that
APOE is the major susceptibility gene for AD [26]. Any
additional susceptibility loci for AD are therefore likely to
have much smaller effects, demanding very large sample
sizes for detection.
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